Abstract
AbstractMyelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disease (MOGAD) is increasingly recognized as a distinct nosological entity from aquaporin‐4 antibody IgG–positive neuromyelitis optica spectrum disorder (AQP4‐IgG NMOSD). The advent of highly specific MOG‐IgG cell‐based diagnostic assays have helped to refine our understanding of the clinical spectrum of MOGAD. To date, treatment approaches have been largely extrapolated from AQP4‐IgG NMOSD experience, but there is growing evidence of distinct differences in treatment response between these conditions. This review summarizes the current status and understanding of acute and chronic treatments for MOGAD. Timing and duration of treatment, pregnancy, and emerging therapies are also discussed.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
